Literature DB >> 3146327

Selenium treatment in neuronal ceroid-lipofuscinosis.

S Naidu1, I Maumanee, J Olson, J Borel, H Moser.   

Abstract

Neuronal ceroid-lipofuscinosis (NCL) refers to a group of disorders with devastating effects on the central nervous system. The accumulation of autofluorescent lipopigments containing lipid peroxides is considered a pathogenetic mechanism of the cell damage seen in NCL. Therapy aimed at preventing further lipid peroxidation, such as the Zeman regimen, did not slow progression of the disease. Therefore, Santavuori and Westermarck [Santavuori and Westermarck 1984] introduced treatment with a combination of selenium and vitamin E and reported favorable results with few side effects. We present information on the rationale for the use of selenium, recommendations on the daily intake, and reported side effects. However, our limited experience with selenium in this disorder does not permit conclusions. Additionally, careful studies are indicated before this treatment is dispensed routinely.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146327     DOI: 10.1002/ajmg.1320310631

Source DB:  PubMed          Journal:  Am J Med Genet Suppl        ISSN: 1040-3787


  4 in total

1.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

2.  Selenium in serum as a possible parameter for assessment of breast disease.

Authors:  H Krsnjavi; D Beker
Journal:  Breast Cancer Res Treat       Date:  1990-07       Impact factor: 4.872

3.  Spielmeyer-Vogt disease: clinical and neurophysiological aspects.

Authors:  L Piattella; C Cardinali; N Zamponi; O Papa
Journal:  Childs Nerv Syst       Date:  1991-08       Impact factor: 1.475

Review 4.  Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.

Authors:  Ryan D Geraets; Seung yon Koh; Michelle L Hastings; Tammy Kielian; David A Pearce; Jill M Weimer
Journal:  Orphanet J Rare Dis       Date:  2016-04-16       Impact factor: 4.123

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.